Evidence map›Paper›PMID 28222813›Full record

ArticleParasites & vectors2017

Comparative speed of kill of sarolaner (Simparica

Raj Packianathan, Andrew Hodge, Natalie Bruellke, Kylie Davis, Steven Maeder

Open access · goldAbstract readComparative Study
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Approaches to Integrated Parasite Management (IPM) forPathogens (Basel, Switzerland) · 2021
    Review
  3. Protecting dogs and cats against the Australian paralysis tick,Current research in parasitology & vector-borne diseases · 2021
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Efficacy of sarolaner (SimparicaParasites & vectors · 2019
    Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Raj PackianathanZoetis Australia Research and Manufacturing Pty Ltd, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia. raj.packianathan@zoetis.com.
Andrew HodgeZoetis Australia Research and Manufacturing Pty Ltd, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia.
Natalie BruellkeZoetis Australia Research and Manufacturing Pty Ltd, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia.
Kylie DavisZoetis Australia Research and Manufacturing Pty Ltd, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW, 2138, Australia.
Steven MaederZoetis, Veterinary Medicine Research and Development, 333 Portage St, Kalamazoo, MI, 49007, USA.
Zoetis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Australian paralysis tick, Ixodes holocyclus, causes paralysis predominantly in dogs and cats in the Eastern coastal regions of Australia. Rapid onset of effect of a parasiticide is critical to minimize the deleterious effects of these tick infestations, especially tick paralysis caused by the salivary neurotoxin. The speed of kill of a novel orally administered isoxazoline parasiticide, sarolaner chewable tablets (Simparica

methodsTwenty-four (24) dogs were randomly allocated to treatment with either placebo, sarolaner (label dose of 2 to 4 mg/kg as per dosing table), or afoxolaner (label dose of 2.7 to 6.9 mg/kg) based on pre-treatment body weights. Following artificial infestation on Day -1, dogs were examined and live ticks counted at 8, 12, 24 and 48 h after treatment on Day 0, and at 12, 24 and 48 h after subsequent re-infestations on Days 7, 14, 21, 28 and 35. Efficacy was determined at each time point relative to counts for placebo dogs based on geometric means.

resultsAt 8 and 12 h time points on Day 0, sarolaner-treated dogs had significantly lower geometric mean tick counts compared to the dogs treated with afoxolaner (P ≤ 0.0303). Efficacy of sarolaner against an existing infestation was 86.2 and 96.9% compared with that of afoxolaner which had efficacy of 21.3 and 85.0% at 8 and 12 h time points, respectively. Against subsequent weekly re-infestations at 12 h time points, treatment with sarolaner resulted in significantly lower geometric mean tick counts than afoxolaner-treated dogs on all days (P ≤ 0.0077) with the efficacy ranging from 60.2 to 92.2%, compared to 5.8 to 61.0% in the afoxolaner-treated dogs. Against subsequent weekly re-infestations at the 24 h time points on Days 22 and 36, efficacy of sarolaner was significantly higher at 99.2 and 97.9%, respectively, compared with afoxolaner which had efficacy of 92.4 and 91.9% (P ≤ 0.0356). At the 48 h time points following each of the five weekly re-infestations, the mean efficacy results of sarolaner and afoxolaner treated dogs were similar on most occasions. There were no adverse reactions to treatments.

conclusionsIn this controlled laboratory evaluation, a single dose of sarolaner had a significantly faster speed of kill against an existing infestation of I. holocyclus, than afoxolaner at 8 and 12 h post-treatment. The rapid and consistent kill of ticks provided by sarolaner within 24 h after a single oral dose and following weekly re-infestations over 35 days suggests this treatment will provide highly effective, rapid and reliable control of ticks over the entire treatment interval, thereby minimizing the risk of tick paralysis in dogs.

Indexed as

AnimalsAustraliaAzetidinesDog DiseasesDogsIsoxazolesIxodesNaphthalenesParasite LoadPlacebosRandom AllocationSpiro CompoundsSurvival AnalysisTick InfestationsTime FactorsafoxolanerAzetidinesIsoxazolesNaphthalenesPlacebossarolanerSpiro CompoundsAfoxolanerDogIsoxazolineIxodes holocyclusNexGard®OralSarolanerSimparica®Speed of killTick

Identifiers

PMID28222813
PMCPMC5320688
OpenAlexW3145769675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.